8-K - Haymaker Acquisition Corp. III | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Biote Corp posted an updated investor presentation on April 3, 2026, highlighting its 2025 financial performance, business model, and expansion opportunities in therapeutic wellness.

Key Takeaways

1Biote reported 2025 revenue of $192.2 million and adjusted EBITDA of $53.5 million with a 27.8% margin.

2The company has over 9,200 certified practitioners and approximately 400,000 active patients as of December 31, 2025.

3Biote is expanding beyond hormone optimization into new therapeutic wellness categories including weight loss, sexual health, and aesthetics.

4The company repurchased approximately 5.5 million shares of its Class V voting stock for $25.1 million.

5Biote operates in large addressable markets including a $400+ billion therapeutic wellness market and $7+ billion hormone replacement market.

Current Report Details

Event Type

Regulation Fd

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, including Exhibit 99.1 . | Item 9.01. | Financial Statements and Exhibits. | |---|---| (d) Exhibits. Exhibit No.: 99.1 | Description: Investor Presentation. E

Regulation Fd

Results of Operations

Fiscal Year 2025

Metric	Value	Basis
Revenue	$192.20
Adjusted EBITDA	$53.50	Non-GAAP
Adjusted EBITDA Margin	27.8%	Non-GAAP

Capital Return

Buyback Auth.

Company repurchased approximately 5.5M shares of its Class V voting stock for $25.1M

Exhibits (2)

8-K

99.1

EX-99.1